Skip to content

NMN for Menopause & Perimenopause: What the Evidence Shows

NMN has a metabolic trial in postmenopausal women, but it does not establish symptom relief. Sleep studies also do not prove a menopause benefit.

By Marcus HaleLongevity Research Editor
Updated

6 min read · 8 sources

On this page

NMN (nicotinamide mononucleotide) has become a fixture in the perimenopause and menopause wellness conversation — marketed for hot flashes, night sweats, brain fog, low energy, poor sleep, and "hormonal balance." The pitch leans on a real and intuitive idea: NAD+ falls with age, menopause is a time of accelerated change, so topping up NAD+ should help. But the honest headline — the one the marketing buries — has to come first: NMN has not been established as a treatment for menopause symptoms. Its postmenopausal metabolic trial does not show symptom relief. A newer menopause pilot tested NR plus pterostilbene, a different combination, and had no placebo group 8. This page maps exactly what's proven, what's extrapolated, and where the evidence simply isn't.

Changes in skin and changes in hair density are different questions. Our hair-growth evidence guide examines what follicle experiments and limited clinical observations establish for NMN and NAD+.

Affiliate partner

Peter MD

Physician-prescribed injectable NAD+, sold as a course rather than a monthly plan

See Peter MD

A framing point to keep throughout: NMN is a dietary supplement, not an approved treatment for menopause. Nothing below should be read as a reason to skip evidence-based menopause care.

Why NAD+ is even in the menopause conversation

The biological rationale isn't fabricated. NAD+ is the central coenzyme of energy metabolism and a fuel for the sirtuin enzymes involved in metabolic and cellular health, and tissue NAD+ levels decline with age across the body 1. Many of the things women notice in the menopause transition — flagging energy, disrupted sleep, shifting metabolism and body composition, more stubborn weight — overlap with the downstream effects of declining NAD+ and mitochondrial function, which is why NMN gets marketed for midlife weight change as hard as it is marketed for the symptoms themselves. Reviews of NAD+-dependent biology in women's health (the sirtuin pathways in particular) lay out why the pathway is plausibly relevant to female aging 3, and the NAD+/ovarian-aging literature shows the coenzyme is genuinely tied to reproductive aging 2.

So the rationale is reasonable: midlife is a period of NAD+ decline layered on top of estrogen withdrawal, and topping up NAD+ might ease some of the metabolic and energy changes. The question is whether "might" has been converted into "does" for menopause — and it hasn't.

The proposed rationale

Aging

NAD+ declines with age (human)

Less NAD+ / sirtuin fuel

Overlaps with midlife energy & metabolic shifts

NMN proposed to top up NAD+

Reliably raises blood NAD+

Eases menopause symptoms?

No established NMN symptom benefit

The mechanism is plausible; the cited NMN trials do not establish menopause symptom relief.

The gap is evidence for menopause symptom relief

The key question is whether NMN improves hot flashes, night sweats or validated menopause symptom scores. The NMN trials discussed below do not establish that benefit. Enrolling postmenopausal women for an insulin-sensitivity study is not equivalent to testing treatment of menopause symptoms.

There is now adjacent clinical research, which should be described precisely. A May 2026 paper reported an open-label pilot in 40 women given 250 mg/day NR plus 50 mg/day pterostilbene for seven days; 32 reported menopausal symptoms. Symptom scores improved from baseline, but all participants received the combination. The eight women with few or no symptoms were not a placebo group. The study was short, included manufacturer-affiliated authors, and cannot isolate an NR effect or establish durable benefit 8. It is not evidence that NMN relieves hot flashes.

Menopause claims readout

  • NAD+ decline relevant to female / metabolic agingModerate evidence

    Human review and mechanistic data tie NAD+/sirtuins to aging and reproductive aging. The rationale is real.

  • NMN → insulin sensitivity in postmenopausal womenModerate evidence

    One RCT in prediabetic postmenopausal women. A metabolic marker — NOT a menopause symptom.

  • NMN → general sleep / fatigue (older adults)Weak evidence

    Mixed-sex trial not selected for menopause symptoms; evening placebo also improved, and overall sleep-quality interaction was not significant.

  • NMN → hot flashes / night sweats / menopause symptomsNone evidence

    NMN symptom efficacy is unestablished; the 2026 pilot used NR plus pterostilbene without placebo.

The NR-combination pilot adds preliminary symptom research, but does not establish NMN efficacy.

What the actual NMN trials measured (and in whom)

To be fair to the supplement, it's worth seeing what the real human NMN trials did show — and noticing how far each sits from a menopause claim.

  • Sleep and fatigue (general aging, not menopause). The most-cited "energy and sleep" trial gave 250 mg of NMN daily for 12 weeks to older Japanese adults — a mixed-sex group not selected for menopause symptoms. Its PM dose was taken from 6 p.m. to bedtime. Although the evening NMN group had larger within-group changes in some measures, evening placebo also reduced drowsiness and the overall sleep-quality group-by-time test was not significant 4. This is the single study most often invoked for "NMN helps menopausal sleep and energy" — but it neither studied menopause nor measured a menopause symptom.
  • Metabolism in postmenopausal women. The one trial actually done in postmenopausal women tested NMN in prediabetic, postmenopausal women and found it improved muscle insulin sensitivity 5. That's a genuine, well-conducted result — but the endpoint was a metabolic marker, not a menopause symptom. It tells us NMN can engage metabolism in this population; it does not tell us it relieves hot flashes, night sweats, or mood.
  • General middle-age supplementation. A larger randomized trial in healthy middle-aged adults found NMN reliably raised blood NAD+ and reported some changes in fitness/physical metrics 6, consistent with NMN mostly raising NAD+ in mice and people 7. Again: NAD+ goes up; menopause symptoms were never measured.

Read together, the human NMN evidence establishes two honest facts: NMN reliably raises NAD+, and in specific aging populations it has produced some metabolic and physical-function signals. It does not establish that NMN relieves menopause symptoms.

Where the marketing outruns the evidence

The leap happens in three predictable places, and it's worth naming each:

  1. "NMN helps menopausal sleep and energy" borrows the older-adult sleep/fatigue trial 4 — a mixed-sex study not selected for menopause symptoms, with no significant overall sleep-quality interaction — and re-labels it as a menopause benefit.
  2. "NMN balances hormones" has no support at all; NMN is not a hormone and no trial has shown it changes estrogen, progesterone, or vasomotor symptoms.
  3. "NMN for hot flashes/night sweats" is the cleanest example of a claim with literally no human data behind it.

Meanwhile, the treatments that do have strong randomized evidence for menopausal symptoms — menopausal hormone therapy for vasomotor symptoms, and several non-hormonal prescription options — are exactly the ones an NMN bottle quietly competes with. That's the real cost of the hype: it can pull attention and money away from menopause care that actually works.

Safety — and why "probably harmless" isn't the whole answer

For general wellness use, oral NMN has been well tolerated in the trials that exist, with mostly mild effects 56. The bigger issue for menopause isn't acute safety — it's opportunity cost and false reassurance. Treating bothersome hot flashes, sleep-wrecking night sweats, or mood changes with an unproven supplement can delay effective, evidence-based care. NMN is also not a substitute for the bone, cardiovascular, and metabolic management that the menopause transition makes more important.

Anyone considering NMN in midlife should treat it as an experimental, general-aging supplement — reasonable to discuss with a clinician, but not a menopause treatment — and should bring genuine menopause symptoms to a clinician who can offer therapies with actual trial evidence.

The honest bottom line

The NAD+-and-menopause idea is biologically plausible: NAD+ falls with age 1, the pathway is tied to female and reproductive aging 23, and NMN reliably raises NAD+ 7. But plausibility is where this story stops. NMN has no established efficacy for hot flashes or night sweats. The closest human data are a general older-adult sleep/fatigue trial 4 and a metabolic trial in postmenopausal women 5 — neither of which measured a menopause outcome. So NMN for menopause belongs firmly in the "mechanism-plausible, human-untested" column, and it is not a substitute for evidence-based menopause care. For the broader picture, see our pillar guide to NAD+ therapy and our look at the wider women's-health claims in NAD+ for women; the related egg-quality claim gets its own honest review in NMN for fertility and egg quality; and for the sleep angle specifically, see NMN for sleep and insomnia. To compare products on dose, form, and testing, see our NAD+ rankings hub.

This is consumer education, not medical advice. NMN is a dietary supplement, not an approved menopause treatment, and is unstudied for menopause symptoms. If you have bothersome menopause symptoms, talk to a clinician about therapies with proven evidence.

Frequently asked questions

Does NMN help with hot flashes or night sweats?

NMN has no established benefit for these symptoms. A 2026 seven-day pilot reported symptom improvements with NR plus pterostilbene, but it used a different combination and no placebo. It cannot establish that NMN treats hot flashes. If hot flashes or night sweats are disrupting your life, the treatments with strong trial evidence (such as menopausal hormone therapy and certain non-hormonal prescriptions) are worth discussing with a clinician.

Is there any human trial of NMN for menopause?

There is a randomized metabolic trial in prediabetic postmenopausal women, but it did not test menopause symptom relief. The older-adult sleep study also does not establish a menopause benefit. The separate 2026 menopause pilot tested NR plus pterostilbene, not NMN, without a placebo group.

Can NMN balance my hormones?

No. NMN is not a hormone and there is no evidence it changes estrogen, progesterone, or vasomotor symptoms. 'Hormone balancing' is a marketing phrase, not a tested effect of NMN. NMN's documented action is raising NAD+ — which is not the same as altering reproductive hormones or relieving menopausal symptoms.

Could NMN still help with menopausal energy or sleep?

Possibly, but it's unproven for that purpose. The older-adult timing trial was not selected for menopause symptoms. The later NMN group took it from 6 p.m. to bedtime, placebo also improved in drowsiness, and overall sleep-quality differences were not significant. Those results do not establish menopausal sleep or fatigue relief.

Is NMN safe to take during perimenopause or menopause?

In the trials that exist, oral NMN has generally been well tolerated with mild effects. The bigger issue isn't acute safety — it's opportunity cost: relying on an unproven supplement can delay effective, evidence-based menopause care. Treat NMN as an experimental general-aging supplement, not a menopause treatment, and bring real menopause symptoms to a clinician who can offer proven options.

References

  1. Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. https://pubmed.ncbi.nlm.nih.gov/33353981/
  2. Liang J, Huang F, Song Z, et al. (2023). Impact of NAD+ metabolism on ovarian aging. Immunity & Ageing. https://pubmed.ncbi.nlm.nih.gov/38041117/
  3. Madhusudhana R, et al. (2025). Sirtuins in Women's Health. Pharmaceuticals (Basel). https://pubmed.ncbi.nlm.nih.gov/41471349/
  4. Kim M, Seol J, Sato T, et al. (2022). Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients. https://pubmed.ncbi.nlm.nih.gov/35215405/
  5. Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. https://pubmed.ncbi.nlm.nih.gov/33888596/
  6. Yi L, Maier AB, Tao R, et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. https://pubmed.ncbi.nlm.nih.gov/36482258/
  7. Mills KF, Yoshida S, Stein LR, et al. (2016). Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/28068222/
  8. Holmes HE, Srivastava K, Scalici JM, et al. (2026). Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial. Frontiers in Aging. https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2026.1773667/full

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.